🍂 Enjoy the Fall Season! 🍂
MindTheDesk

2026 ESMO | Innovent Presents Multiple Clinical Data Updates for IBI363/TAK-928, a PD-1/Alpha-Biased IL-2 Bispecific Fusion Protein

Gillette Archived • October 25, 2026 • 2 views
2026 ESMO | Innovent Presents Multiple Clinical Data Updates for IBI363/TAK-928, a PD-1/Alpha-Biased IL-2 Bispecific Fusion Protein
The data showcased are from three Phase 1b clinical studies of IBI363/TAK-928 in first-line NSCLC, first-line G/GEJA, and immunotherapy-resistant lung adenocarcinoma, further supporting its potential clinical value across treatment settings.
Source: Gillette News Record | https://www.gillettenewsrecord.com/search/?f=rss&t=article&l=50&s=start_time&sd=desc - Read Original
"What you put in is not always what you get out."
"Output is a realization of Input."

Discussion (0)

Please log in to post a comment.

No comments yet. Be the first to share your thoughts!

Sponsored
"Cardamom Spices and more to satisfy the tastebuds 100g $14.94"
"Network Cable Repairs from $29"